Rising US Sales, EU Milestone Boost SK Bio's Q1
Shift To Operating Profit
Executive Summary
After strong first-quarter results, SK Biopharmaceuticals expects sales growth to accelerate as the US marketing environment improves and as EU sales of epilepsy drug cenobamate begin.